In a regulatory filing, ShotSpotter disclosed that its CFO Alan Stewart bought 7.5K shares of common stock on March 3rd in a total transaction size of $285K.

In a regulatory filing, Square disclosed that its director Mary Meeker sold 8.2K shares of common stock on March 2nd in a total transaction size of $2.07M, reducing her holding by 2%.

In a regulatory filing, TriMas director Herbert K. Parker disclosed the sale of 21,158 common shares of the company on March 2 at a price of $32.16 per share.

In a regulatory filing, PDC Energy director Anthony J. Crisafio disclosed the sale of 17,000 common shares of the company on March 3 at a price of $36.30 per share.

This is the lowest level of holdings since May 7th, 2020.

In an interview on CNBC's Mad Money, Doug Merritt said, "It's a tale of two businesses for Splunk." The company is growing cloud revenue very quickly he noted. Merritt said Splunk corrected in Q4 and changed a lot of its methodologies. "We're making long term investments for the health of our customers," he added.

On March 3, Oportun, Inc. a subsidiary of Oportun Financial Corporation, received a Civil Investigative Demand from the Consumer Financial Protection Bureau. The stated purpose of the CID is to determine whether small-dollar lenders or associated persons, in connection with lending and debt-collection practices, have not been in compliance with certain federal consumer protection laws over which the CFPB has jurisdiction, the company disclosed in a regulatory filing. The information requests in the CID focus on Oportun's legal collection practices from 2019 to 2021 and hardship treatments offered during the COVID-19 pandemic. "The Company believes its practices have been in full compliance with CFPB guidance and that it has followed all published authority with respect to its practices, and the Company intends to cooperate with the CFPB. At this time, the Company is unable to predict the outcome of this CFPB investigation, including whether the investigation will result in any action or proceeding against the Company or in any changes to its practices," it said.

The company states: "Genentech, a member of the Roche Group,announced that the FDA approved Actemra, or tocilizumab, subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease, a debilitating condition with limited treatment options. Actemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis, also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. It occurs when the immune system malfunctions causing tissues of the skin and lungs to thicken and harden. SSc impacts up to 75,000 people in the United States. Interstitial lung disease, which may occur in approximately 80% of SSc patients, causes inflammation and scarring of the lungs and can be life-threatening. The FDA approval is based on data from the focuSSced trial, a Phase III randomized, double-blind, placebo-controlled clinical trial of 212 adults with systemic sclerosis. Supportive information was also used from the faSScinate trial, a Phase II/III, randomized, double-blind, placebo-controlled study in patients with SSc. The focuSSced trial did not meet its primary endpoint of change from baseline to week 48 in the modified Rodnan Skin Score, which is a standard outcome measure for skin fibrosis in SSc. There also was not a statistically significant effect on the primary endpoint of mRSS in the faSScinate trial."

Avery Dennison VP Deena Baker disclosed in a filing that she had sold 2,500 shares of company stock at $179.46 per share on March 3, for a total transaction amount of $448,653.